Fosamax Side Effects

Generic name: alendronate

Please note - some side effects for Fosamax may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

Side Effects of Fosamax - for the consumer

Fosamax

All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Fosamax:

Bone, muscle, or joint pain; constipation; diarrhea; dizziness; feeling bloated or full; flu-like symptoms at the start of treatment; gas; headache; mild stomach pain; nausea; taste changes; vomiting.

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry, or bloody stools; chest pain; coughing or vomiting blood; difficult or painful swallowing; mouth sores; new, worsening, or severe heartburn; red, swollen, blistered, or peeling skin; severe bone, muscle, or joint pain; severe or persistent sore throat or stomach pain; swelling of the hands, legs, or joints; swelling or pain in the jaw.

Fosamax Plus D

All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Fosamax Plus D:

Bone, muscle, or joint pain; constipation; diarrhea; dizziness; feeling bloated or full; flu-like symptoms at the start of treatment; gas; headache; mild stomach pain; nausea; taste changes; vomiting.

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry, or bloody stools; chest pain; coughing or vomiting blood; difficult or painful swallowing; mouth sores; new, worsening, or severe heartburn; red, swollen, blistered, or peeling skin; severe bone, muscle, or joint pain; severe or persistent sore throat or stomach pain; swelling of the hands, legs, or joints; swelling or pain in the jaw.

Fosamax Solution

All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Fosamax Solution:

Bone, muscle, or joint pain; constipation; diarrhea; dizziness; feeling bloated or full; flu-like symptoms at the start of treatment; gas; headache; mild stomach pain; nausea; taste changes; vomiting.

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry, or bloody stools; chest pain; coughing or vomiting blood; difficult or painful swallowing; mouth sores; new, worsening, or severe heartburn; red, swollen, blistered, or peeling skin; severe bone, muscle, or joint pain; severe or persistent sore throat or stomach pain; swelling of the hands, legs, or joints; swelling or pain in the jaw.

For the professional

Fosamax

Clinical Studies

In clinical studies of up to five years in duration adverse experiences associated with Fosamax usually were mild, and generally did not require discontinuation of therapy.

Fosamax has been evaluated for safety in approximately 8000 postmenopausal women in clinical studies.

Postmenopausal women

In two identically designed, three-year, placebo-controlled, double-blind, multicenter studies (United States and Multinational; n=994), discontinuation of therapy due to any clinical adverse experience occurred in 4.1% of 196 patients treated with Fosamax 10 mg/day and 6.0% of 397 patients treated with placebo. In the Fracture Intervention Trial (n=6459), discontinuation of therapy due to any clinical adverse experience occurred in 9.1% of 3236 patients treated with Fosamax 5 mg/day for 2 years and 10 mg/day for either one or two additional years and 10.1% of 3223 patients treated with placebo. Discontinuations due to upper gastrointestinal adverse experiences were: Fosamax, 3.2%; placebo, 2.7%. In these study populations, 49-54% had a history of gastrointestinal disorders at baseline and 54-89% used nonsteroidal anti-inflammatory drugs or aspirin at some time during the studies. Adverse experiences from these studies considered by the investigators as possibly, probably, or definitely drug related in ≥1% of patients treated with either Fosamax or placebo are presented in the following table.

Rarely, rash and erythema have occurred.

One patient treated with Fosamax (10 mg/day), who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant aspirin developed an anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and Fosamax were discontinued and the patient recovered.

The adverse experience profile was similar for the 401 patients treated with either 5 or 20 mg doses of Fosamax in the United States and Multinational studies. The adverse experience profile for the 296 patients who received continued treatment with either 5 or 10 mg doses of Fosamax in the two-year extension of these studies (treatment years 4 and 5) was similar to that observed during the three-year placebo-controlled period. During the extension period, of the 151 patients treated with Fosamax 10 mg/day, the proportion of patients who discontinued therapy due to any clinical adverse experience was similar to that during the first three years of the study.

In a one-year, double-blind, multicenter study, the overall safety and tolerability profiles of once weekly Fosamax 70 mg and Fosamax 10 mg daily were similar. The adverse experiences considered by the investigators as possibly, probably, or definitely drug related in ≥1% of patients in either treatment group are presented in the following table.

Men

In two placebo-controlled, double-blind, multicenter studies in men (a two-year study of Fosamax 10 mg/day and a one-year study of once weekly Fosamax 70 mg) the rates of discontinuation of therapy due to any clinical adverse experience were 2.7% for Fosamax 10 mg/day vs. 10.5% for placebo, and 6.4% for once weekly Fosamax 70 mg vs. 8.6% for placebo. The adverse experiences considered by the investigators as possibly, probably, or definitely drug related in ≥2% of patients treated with either Fosamax or placebo are presented in the following table.

The safety of Fosamax 5 mg/day in postmenopausal women 40-60 years of age has been evaluated in three double-blind, placebo-controlled studies involving over 1,400 patients randomized to receive Fosamax for either two or three years. In these studies the overall safety profiles of Fosamax 5 mg/day and placebo were similar. Discontinuation of therapy due to any clinical adverse experience occurred in 7.5% of 642 patients treated with Fosamax 5 mg/day and 5.7% of 648 patients treated with placebo.

In a one-year, double-blind, multicenter study, the overall safety and tolerability profiles of once weekly Fosamax 35 mg and Fosamax 5 mg daily were similar.

The adverse experiences from these studies considered by the investigators as possibly, probably, or definitely drug related in ≥1% of patients treated with either once weekly Fosamax 35 mg, Fosamax 5 mg/day or placebo are presented in the following table.

In two studies (of one and two years' duration) of postmenopausal osteoporotic women (total: n=853), the safety and tolerability profile of combined treatment with Fosamax 10 mg once daily and estrogen ± progestin (n=354) was consistent with those of the individual treatments.

In two, one-year, placebo-controlled, double-blind, multicenter studies in patients receiving glucocorticoid treatment, the overall safety and tolerability profiles of Fosamax 5 and 10 mg/day were generally similar to that of placebo. The adverse experiences considered by the investigators as possibly, probably, or definitely drug related in ≥1% of patients treated with either Fosamax 5 or 10 mg/day or placebo are presented in the following table.

The overall safety and tolerability profile in the glucocorticoid-induced osteoporosis population that continued therapy for the second year of the studies (Fosamax: n=147) was consistent with that observed in the first year.

In clinical studies (osteoporosis and Paget's disease), adverse experiences reported in 175 patients taking Fosamax 40 mg/day for 3-12 months were similar to those in postmenopausal women treated with Fosamax 10 mg/day. However, there was an apparent increased incidence of upper gastrointestinal adverse experiences in patients taking Fosamax 40 mg/day (17.7% Fosamax vs. 10.2% placebo). One case of esophagitis and two cases of gastritis resulted in discontinuation of treatment.

Additionally, musculoskeletal (bone, muscle or joint) pain, which has been described in patients with Paget's disease treated with other bisphosphonates, was considered by the investigators as possibly, probably, or definitely drug related in approximately 6% of patients treated with Fosamax 40 mg/day versus approximately 1% of patients treated with placebo, but rarely resulted in discontinuation of therapy. Discontinuation of therapy due to any clinical adverse experience occurred in 6.4% of patients with Paget's disease treated with Fosamax 40 mg/day and 2.4% of patients treated with placebo.

Fosamax is not indicated for use in children.

The overall safety profile of Fosamax in OI patients treated for up to 24 months was generally similar to that of adults with osteoporosis treated with Fosamax. However, there was an increased occurrence of vomiting in OI patients treated with Fosamax compared to placebo. During the 24-month treatment period, vomiting was observed in 32 of 109 (29.4%) patients treated with Fosamax and 3 of 30 (10%) patients treated with placebo.

In a pharmacokinetic study, 6 of 24 pediatric OI patients who received a single oral dose of Fosamax 35 or 70 mg developed fever, flu-like symptoms, and/or mild lymphocytopenia within 24 to 48 hours after administration. These events, lasting no more than 2 to 3 days and responding to acetaminophen, are consistent with an acute-phase response that has been reported in patients receiving bisphosphonates, including Fosamax. See ADVERSE REACTIONS, Post-Marketing Experience, Body as a Whole.

In double-blind, multicenter, controlled studies, asymptomatic, mild, and transient decreases in serum calcium and phosphate were observed in approximately 18% and 10%, respectively, of patients taking Fosamax versus approximately 12% and 3% of those taking placebo. However, the incidences of decreases in serum calcium to <8.0 mg/dL (2.0 mM) and serum phosphate to ≤2.0 mg/dL (0.65 mM) were similar in both treatment groups.

Post-Marketing Experience

The following adverse reactions have been reported in post-marketing use:

Body as a Whole: hypersensitivity reactions including urticaria and rarely angioedema. Transient symptoms of myalgia, malaise, asthenia and rarely, fever have been reported with Fosamax, typically in association with initiation of treatment. Rarely, symptomatic hypocalcemia has occurred, generally in association with predisposing conditions. Rarely, peripheral edema.

Gastrointestinal: esophagitis, esophageal erosions, esophageal ulcers, rarely esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe and with complications have also been reported.

Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection, often with delayed healing, has been reported rarely.

Musculoskeletal: bone, joint, and/or muscle pain, occasionally severe, and rarely incapacitating; joint swelling.

Nervous system: dizziness and vertigo.

Skin: rash (occasionally with photosensitivity), pruritus, alopecia, rarely severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.

Special Senses: rarely uveitis, scleritis or episcleritis.

By body system

General side effects

Generally, alendronate has been well tolerated. Adverse effects usually have been mild when patients adhered to prescribing instructions.

Fever has been reported in patients receiving intravenous infusions of alendronate.

Asthenia and rare instances of peripheral edema have been reported in postmarketing experience.

Gastrointestinal side effects

Gastrointestinal side effects have included abdominal pain, nausea, dyspepsia, constipation, diarrhea, and flatulence. Regurgitation, esophageal ulcer, vomiting, dysphagia, abdominal distention, and gastritis also have occurred. Rarely, taste perversion has been reported. The frequency of adverse effects increased with higher dosages.

Several cases of ulcerative esophagitis have been reported in patients receiving alendronate. Patients with preexisting esophageal disorders and those who take alendronate with little or no water and lie down immediately following ingestion may be at an increased risk.

Postmarketing experience has reported esophagitis, esophageal erosions, esophageal ulcers, rarely esophageal stricture or perforation and oropharyngeal ulceration.

The combination of alendronate and naproxen has been reported as synergistic for development of gastric ulcers.

Metabolic side effects

Metabolic side effects have included reductions in serum calcium and phosphate levels as a result of the inhibition of bone resorption. These reductions generally have been mild, asymptomatic, and transient. Symptomatic hypocalcemia has been reported in postmarketing experiences.

Musculoskeletal side effects

Musculoskeletal side effects have included bone, muscle or joint pain in approximately 4% of patients. In postmarketing experience, severe and occasionally incapacitating bone, joint and/or muscle pain, have been infrequently reported. Localized osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection, often with delayed healing, has been reported rarely. Joint swelling has been reported postmarketing experience.

Nervous system side effects

Nervous system side effects have been rare. Headaches have been reported in fewer than 3% of patients. Dizziness and vertigo have been reported in postmarketing experience.

Dermatologic side effects

Dermatologic side effects have included rare reports of rash and erythema. Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in postmarketing experiences.

Ocular side effects

Ocular side effects have included rare incidences of iritis, scleritis, uveitis, and nonspecific transitory conjunctivitis.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.